Antiplatelet and Anticoagulation Therapies

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, international normalized ratio (INR) testing, oral anticoagulants, IV administered drugs such as Heprin, and dual antiplatelet therapy (DAPT). The most commonly used anticoagulant is warfarin, which available in generic form at a low cost. However, it has a narrow therapeutic window and its effectiveness is altered by food containing vitamin K. To regulate warfarin, regular INR testing is needed. The newer anticoagulation drugs are referred to as novel oral anticoagulant (NOAC). However, since some of these drugs are now more than six years old, they are commonly referred to as non-vitamin K oral anticoagulant (NOAC), and the newest term, direct oral anticoagulant (DOAC). NOAC or DOAC agents have much larger therapeutic windows, do not require INR testing. Aspirin and clopidogrel (Plavix) are the most commonly used antiplatelet agents for the prevention of heart attacks and stroke. They are often prescribed together as DAPT.

Videos | TCT | November 18, 2016
DAIC Editor Dave Fornell takes a video tour of some of the most innovative new interventional cardiology technologies...
atrial fibrillation, warfarin, dementia, Intermountain Medical Center Heart Institute, American Heart Association, AHA Scientific Sessions 2016
News | Atrial Fibrillation | November 15, 2016
November 15, 2016 — Atrial fibrillation patients who use warfarin to lower risk of stroke are at higher risk of...
bivalirudin, heparin, blood clot prevention medication, PCI, percutaneous coronary intervention, Intermountain study, AHA Scientific Sessions
News | Antiplatelet and Anticoagulation Therapies | November 14, 2016
November 14, 2016 — Two differing blood clot prevention medications are just as safe and effective for patients...
Siemens, FDA clearance, Xprecia Stride Coagulation Analyzer, point-of-care testing
Technology | Point of Care Testing | November 10, 2016
November 10, 2016 — Siemens Healthineers announced U.S. Food and Drug Administration (FDA) 510(k) clearance for a hand-...
Aggrastat Bolus Vial, IV antiplatelet agent
Technology | Antiplatelet and Anticoagulation Therapies | October 28, 2016
October 28, 2016 — Medicure Inc. recently received U.S. Food and Drug Administration (FDA) market clearance for its new...
UAB, University of Alabama at Birmingham study, stroke prevention, non-valvular atrial fibrillation, NVAF
News | Atrial Fibrillation | October 25, 2016
October 25, 2016 — A recent study from University of Alabama at Birmingham (UAB) researchers published in PLOS ONE ...
Pradaxa, dabigatran, GLORIA-AF registry, ESC Congress 2016, NVAF
News | Antiplatelet and Anticoagulation Therapies | September 01, 2016
September 1, 2016 — First outcome results from the GLORIA-AF Registry show that treatment with Pradaxa (dabigatran...
nanoparticles, blood clotting, internal bleeding, American Chemical Society study, Erin B. Lavik

Nanoparticles (green) help form clots in an injured liver. The researchers added color to the scanning electron microscopy image after it was taken. Image courtesy of Erin Lavik, Ph.D.

News | Hemostasis Management | August 24, 2016
August 24, 2016 — Whether severe trauma occurs on the battlefield or the highway, saving lives often comes down to...
TAILOR-PCI study, antiplatelet medication, genotype, NHLBI grant
News | Antiplatelet and Anticoagulation Therapies | August 18, 2016
August 18, 2016 — Researchers at the Peter Munk Cardiac Centre, Toronto, and at Mayo Clinic are leading the Tailored...
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies | August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in atrial fibrillation may not adequately control blood...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
  August 5, 2016 — Here are the top 20 most popular current content on the Diagnostic and Interventional Cardiology (...
Watchman, left atrial appendage closure, LAA occluder

An illustration of a Watchman transcatheter LAA occluder being implanted.

Feature | Left Atrial Appendage (LAA) Occluders | August 01, 2016 | Dave Fornell
Patients with atrial fibrillation (AF or Afib) are high risk for stroke due to the formation of thrombus emboli in the ...
News | Antiplatelet and Anticoagulation Therapies | July 26, 2016
July 26, 2016 — Hematology researchers at The Children’s Hospital of Philadelphia (CHOP) have developed a novel...
BBMK Technologies, ClotMD mobile app, real-time warfarin management
Technology | Antiplatelet and Anticoagulation Therapies | July 14, 2016
July 14, 2016 — BBMK Technologies recently announced the launch of ClotMD, a cloud-based application and mobile...
Alere, INRatio PT/INR Monitor, voluntary recall, FDA
News | Blood Testing | July 12, 2016
July 12, 2016 — Following a collaborative process with the U.S. Food and Drug Administration (FDA), Alere Inc. will be...